Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: A seven year follow-up

Journal of Urology

Volumn 158, Issue 4, 1997, Pages 1568-1575

  Crundwell, M C ^a   Arkell, D G ^b   Gearty, J ^b   Phillips, S M A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

Genetic alterations; Incidental cancer; Prostate cancer

Indexed keywords

ALPHA CATENIN; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; PROTEIN P53; REGULATOR PROTEIN; UVOMORULIN;

ADULT; AGED; ALLELE; ARTICLE; CELL CYCLE; CHROMOSOME 13Q; CHROMOSOME 8P; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; TRANSITIONAL CELL CARCINOMA;

EID: 0030758982     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64281-2     Document Type: Article

References (38)

1. Anderson, G. A., Lawson, R. K. and Gottlieb, M. S.: Quantitation of potentially undiagnosed incidental carcinoma of the prostate in patients treated non-surgically for benign prostatic hyperplasia. Br. J. Urol., 72: 465, 1993.
2. Blute, M., Zincke, H. and Farrow, G.: Longterm follow up of young patients with stage A adenocarcinoma of the prostate. J. Urol., 136: 840, 1986.
3. Epstein, J. I., Paull, G., Eggleston, J. C. and Walsh, P. C.: Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended follow up. J. Urol, 136: 837, 1986.
4. Benson, M. C., Ring, K. and Giella, J.: Flow cytometry in carcinoma of the prostate. Urol. Clin. North Am., 17: 885, 1990.
5. Lundgren, R., Mandahl, N., Heim, S., Limon, J., Henrikson, H. and Mitelman, F.: Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chrom. Cancer, 4: 16, 1992.
6. Egawa, S., Uchida, T., Suyama, K., Wang, C., Ohori, M., Irie, S., Iwamura, M. and Koshiba, K.: Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables. Cancer Res., 55: 2418, 1995.
7. Netto, G. J. and Humphrey, P. A.: Molecular biologic aspects of human prostatic carcinoma. Am. J. Clin. Pathol., 102: S57, 1994.
8. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. E., Debruyne, F. M. J. and Isaacs, W. B.: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res., 52: 5104, 1992.
9. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma, H. E., Karthaus, H. F. M., Oosterhof, G. O. N., Debruyne, F. M. J. and Schalken, J. A.: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res, 54: 3929, 1994.
10. Ewing, C. M., Ru, N., Morton, R. A., Robinson, J. C., Wheelock, M. J., Johnson, K. R., Barrett, J. C. and Isaacs, W. B.: Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res., 55: 4813, 1995.
11. Bates, T. S., Perry, A., Armstrong, J. and Gingell, J. C.: Expression of three candidate tumour suppressor genes on chromosome 5q, α-catenin, APC and MCC, in prostate cancer. Br. J. Urol., 77 Suppl.: 43, 1996.
12. Gao, X., Honn, K. V., Grignon, D., Sakr, W. and Chen, Y. Q.: Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res., 53: 2723, 1993.
13. Crundwell, M. C., Chughtai, S., Knowles, M., Takle, L., Luscombe, M., Neoptolemos, J. P., Morton, D. G. and Phillips, S. M. A.: Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer. Int. J. Cancer, 69: 295, 1996.
14. Bookstein, R., Rio, P., Madreperla, S. A., Hong, F., Allred, C., Grizzle, W. E. and Lee, W. H.: Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA, 87: 7762, 1990.
15. Phillips, S. M., Morton, D. G., Lee, S. J., Wallace, D. M. and Neoptolemos, J. P.: Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br. J. Urol., 73: 390, 1994.
16. Phillips, S. M. A., Barton, C. M., Lee, S. J., Morton, D. G., Wallace, D. M. A., Lemoine, N. R. and Neoptolemos, J. P.: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostate carcinogenesis. Br. J. Cancer., 70: 1252, 1994.
17. Visakorpi, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T. and Isola, J.: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883, 1992.
18. Vesalainen, S. L., Lipponen, P. K., Talja, M. T., Alhava, E. M. and Syrjanen, K. J.: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2 MO prostatic adenocarcinoma. Int. J. Cancer, 58: 303, 1994.
19. Van Veldhuizen, P. J., Sadasivan, R., Cherian, R., Dwyer, T. and Stephens, R. L.: p53 expression in incidental prostatic cancer. Am. J. Med. Sci., 305: 275, 1993.
20. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z. F., Fuks, Z. and Cordon-Cardo, C.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276, 1994.
21. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C.: J.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
22. Fox, S. B., Persad, R. A., Royds, J., Kore, R. N., Silcocks, P. B. and Collins, C.: C.: p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants? J. Urol., 150: 490, 1993.
23. Bergerheim, U. S., Kunimi, K., Collins, V. P. and Ekman, P.: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chrom. Cancer, 3: 215, 1991.
24. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Aalders, T. W., Schalken, J. A., Epstein, J. I. and Isaacs, W. B.: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. U S A, 87: 8751, 1990.
25. Bova, G. S., Carter, B. S., Bussemakers, M. J., Emi, M., Fujiwara, Y., Kyprianou, N., Jacobs, S. C., Robinson, J. C., Epstein, J. I. and Walsh, P. C., Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res., 53: 3869, 1993.
26. Trapman, J., Sleddens, H.: F., van der Weiden, M. M., Dinjens, W. N., Konig, J. J., Schroder, F. H., Faber, P. W. and Bosman, F. T.: Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res., 54: 6061, 1994.
27. MacGrogan, D., Levy, A., Bostwick, D., Wagner, M., Wells, D. and Bookstein, R.: Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chrom. Cancer, 10: 151, 1994.
28. Macoska, J. A., Trybus, T. M., Benson, P. D., Sakr, W. A., Grignon, D. J., Wonjo, K. D., Pietruk, T. and Powell, I. J.: Evidence for three tumour suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res, 55: 5390, 1995.
29. Gray, I. C., Phillips, S. M., Lee, S. J., Neoptolemos, J. P., Weissenbach, J. and Spurr, N. K.: Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res., 55: 4800, 1995.
30. The British Association of Urological Surgeons TNM Subcommittee: The TNM classification of prostate cancer: a discussion af the 1992 classification. Br. J. Urol., 76: 279, 1995.
31. Nagafuchi, A. and Tsukita, S.: The loss of the expression of alpha-catenin, the 102 kDa Cadherin associated protein, in central nervous tissues during development. Develop. Growth Differ., 36: 59, 1994.
32. Emmert-Buck, M. R., Vocke, C. D., Pozzatti, R. O., Duray, P. H., Jennings, S. B., Florence, C. D., Zhuang, Z., Bostwick, D. G., Liotta, L. A. and Linehan, W. M.: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res., 55: 2959, 1995.
33. Grignon, D. J. and Sakr, W. A.: Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J. Cell Biochem., 19(Suppl.): 267, 1994.
34. Byar, D. P. and Corle, D. K.: The Veterans Administration Cooperative Urological Research Group. Urology, 17 (Suppl.): 1, 1981.
35. Greene, D. R., Egawa, S., Neerhut, G., Flanagan, W., Wheeler, T. M. and Scardino, P. T.: The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J. Urol., 145: 324, 1991.
36. Miller, G. J. and Cygan, J. M.: Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J. Urol., 152: 1709, 1994.
37. McNeal, J. E., Villiers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Capsular penetration in prostate cancer: significance for natural history and treatment. Am. J. Surg. Pathol., 14: 240, 1990.
38. McNeal, J. E. and Bostwick, D. G., Anatomy of the prostate: implications for disease. In: Pathology of the Prostate. Edited by D. G. Bostwick. New York: Churchill Livingstone Inc., pp. 1-14, 1990.